FLGT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FLGT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Fulgent Genetics has the Growth Rank of 7.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.
GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
For the Diagnostics & Research subindustry, Fulgent Genetics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Growth Rank distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's Growth Rank falls into.
Thank you for viewing the detailed overview of Fulgent Genetics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul Kim | officer: CFO and Treasurer | 4399 SANTA ANITA AVE, EL MONTE CA 91731 |
Hanlin Gao | 10 percent owner, officer: Chief Scientific Officer | 4399 SANTA ANITA AVE., EL MONTE CA 91731 |
Jian Xie | officer: Chief Operating Officer | C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVE, EL MONTE CA 91731 |
Ming Hsieh | director, 10 percent owner, officer: President and CEO | 4399 SANTA ANITA AVE., EL MONTE CA 91731 |
Regina E Groves | director | 5751 COPLEY DRIVE, SAN DIEGO CA 92111 |
Leonard E Post | director | |
Michael Nohaile | director | C/O BIO AI ACCELERATION COMPANY, 20 UNIVERSITY AVENUE, CAMBRIDGE MA 02138 |
John C Bolger | director | 4978 SANTA ANITA AVENUE, SUITE 205, TEMPLE CITY CA 91780 |
Ming Hsieh Trust | 10 percent owner | 4399 SANTA ANITA AVE., EL MONTE CA 91731 |
Linda Marsh | director | 100 N. STONEMAN AVE., ROOM 200, ALHAMBRA CA 91801 |
Fulgent Genetics, Inc. | director | 4399 SANTA ANITA AVE, EL MONTE CA 91731 |
Yun Yen | director | 1301 OAKLAWN ROAD, ARCADIA CA 91006 |
James Mulay | director | 6521 THOROUGHBRED LOOP, ODESSA FL 33556 |
Xi Long Usa, Inc. | 10 percent owner | #6 XINRUI RD., SCIENCE CITY, LUOGANG DISTRICT, GUANGZHOU CITY F4 510663 |
From GuruFocus
By GuruFocus Research • 08-05-2024
By GuruFocus News • 11-08-2024
By GuruFocus News • 03-06-2025
By GuruFocus Research • 08-05-2024
By GuruFocus Research • 05-04-2024
By GuruFocus News • 11-20-2024
By Business Wire • 10-31-2024
By Business Wire • 02-06-2025
By GuruFocus Research • 05-04-2024
By GuruFocus News • 01-09-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.